Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus
Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus
复制标题
DOI：
10.1007/s00125-007-0698-9
复制
发表时间：
2007-08-01
期刊：
影响因子：
8.2
通讯作者：
DeFronzo, R. A.
中科院分区：
文献类型：
--
作者：
Bajaj, M.;Suraamornkul, S.;DeFronzo, R. A.
目的/假说本研究的目的是观察PPAR-α激动剂吡格列酮(PTO)和PPAR-α激动剂非诺贝特(FeNO)单独及联合应用对糖脂代谢的影响。受试者分别于术后0、3、6个月接受4h高胰岛素-正血糖钳夹治疗，并测定肝脏脂肪含量。
Aims/hypothesis The aim of the study was to examine the effects of pioglitazone (PTO), a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, and fenofibrate (FENO), a PPAR-alpha agonist, as monotherapy and in combination on glucose and lipid metabolism.Subjects and methods Fifteen type 2 diabetic patients received FENO (n = 8) or PTO (n = 7) for 3 months, followed by the addition of the other agent for 3 months in an open-label study. Subjects received a 4 h hyperinsulinaemic-euglycaemic clamp and a hepatic fat content measurement at 0, 3 and 6 months.Results Following PTO, fasting plasma glucose (FPG) (p